Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### Food and Drug Administration

          - [Docket No. FDA-2022-N-0850]

# AGENCY:

Food and Drug Administration, HHS.

# ACTION:

Notice.

# SUMMARY:

The Food and Drug Administration (FDA or Agency) is announcing that it is withdrawing approval of the indications for relapsed follicular lymphoma and relapsed small lymphocytic lymphoma for ZYDELIG (idelalisib) Tablets, approved under new drug application (NDA) 205858, held by Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, CA 94404 (Gilead). Gilead voluntarily requested that the Agency withdraw approval of these indications and waived its opportunity for a hearing.

# DATES:

Approval is withdrawn as of May 26, 2022.

# FOR FURTHER INFORMATION CONTACT:

                        Kimberly Lehrfeld, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6226, Silver Spring, MD 20993-0002, 301-796-3137,                         *Kimberly.Lehrfeld@fda.hhs.gov.*

# SUPPLEMENTARY INFORMATION:

On July 23, 2014, FDA approved NDA 205858 for ZYDELIG (idelalisib) Tablets for the treatment of patients with relapsed follicular B-cell non-Hodgkin lymphoma in patients who have received at least two prior systemic therapies (the follicular lymphoma indication). On that same day, FDA also approved NDA 205858 for ZYDELIG (idelalisib) Tablets for the treatment of patients with relapsed small lymphocytic lymphoma in patients who have received at least two prior systemic therapies (the SLL indication). FDA approved both the follicular lymphoma indication and the SLL indication under the Agency's accelerated approval regulations, 21 CFR part 314, subpart H. As a condition of accelerated approval of ZYDELIG (idelalisib) Tablets for the follicular lymphoma indication and the SLL indication, the applicant was required to conduct postmarketing trials to verify the clinical benefit of idelalisib for the follicular lymphoma and SLL indications.

On November 22, 2021, FDA met with Gilead to discuss the status of ZYDELIG (idelalisib) Tablet's accelerated approval for the follicular lymphoma indication and the SLL indication, including the continued need for postmarketing trials intended to verify clinical benefit in follicular lymphoma and small lymphocytic lymphoma. FDA raised withdrawal of approval during this discussion, explaining its intent to consult the Oncologic Drugs Advisory Committee (ODAC) on whether FDA should pursue withdrawal of the follicular lymphoma indication and the SLL indication. Subsequently, on December 17, 2021, following further communication with Gilead, FDA advised Gilead that voluntary withdrawal of approval for these indications would be appropriate under § 314.150(d) (21 CFR 314.150(d)). On January 10, 2022, Gilead submitted a letter requesting withdrawal of the follicular lymphoma indication and the SLL indication for ZYDELIG (idelalisib) Tablets and waiving its opportunity for a hearing. Gilead subsequently clarified, on February 23, 2022, that they were requesting the Agency withdraw approval of the follicular lymphoma indication and the SLL indication pursuant to § 314.150(d).

Therefore, under § 314.150(d), approvals of the follicular lymphoma indication and the SLL indication for ZYDELIG (idelalisib) Tablets are withdrawn as of May 26, 2022. Withdrawal of approval of these indications does not affect any other approved indication for ZYDELIG (idelalisib) Tablets.

Dated: May 19, 2022.

Lauren K. Roth,

Associate Commissioner for Policy.

[FR Doc. 2022-11277 Filed 5-25-22; 8:45 am]

BILLING CODE 4164-01-P